Advanced Catheter Therapies

Advanced Catheter Therapies has developed the Pressana OPC, an FDA-cleared catheter system that creates an isolated treatment chamber in blood vessels for the controlled delivery of liquid therapeutic agents. The device is notably the only actively marketed FDA-cleared liquid drug delivery technology approved for below-the-knee applications, addressing a critical unmet need in preventing amputations from peripheral arterial disease. The company, which has raised $8.87 million and generated $7.8 million in sales and licensing to date, is focused on scaling commercialization through a Series C funding round and expanding its distributor network.

The Pressana Occlusion Perfusion Catheter (OPC) is a universal delivery platform that creates an isolated treatment chamber within a blood vessel using occlusion balloons. It allows for controlled flushing, filling, circulation, and evacuation of physician-selected liquid therapeutic agents, with real-time pressure monitoring via an integrated fiberoptic sensor.

The Pressana OPC competes in the peripheral vascular drug delivery space, primarily against drug-coated balloons (DCBs) which are not yet FDA-approved for below-the-knee use. It also competes with other local delivery catheters and standard-of-care therapies without adjunctive drug delivery. Its key competitive advantage is its FDA clearance for BTK use and its versatility with multiple drug types.